The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - AstraZeneca; BeiGene; Bristol-Myers Squibb; Gilead Sciences; Janssen-Cilag; Loxo/Lilly; Novartis; Roche/Genentech; TG Therapeutics
Consulting or Advisory Role - Ascentage Pharma; AstraZeneca; Bristol-Myers Squibb; Gilead Sciences; Janssen-Cilag; Loxo/Lilly; Merck; Roche/Genentech (Inst); TG Therapeutics
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Roche
Pirtobrutinib in covalent BTK-inhibitor (cBTKi) pre-treated mantle cell lymphoma (MCL): Updated results and subgroup analysis from the phase 1/2 BRUIN study with >3 years follow-up from start of enrollment.
 
Nirav Niranjan Shah
Stock and Other Ownership Interests - Tundra Targeted Therapeutics
Consulting or Advisory Role - Incyte; Janssen Oncology; Juno/Bristol-Myers Sqibb; Kite, a Gilead company; Loxo/Lilly; Novartis; Seagen; TG Therapeutics
Research Funding - Adaptive Biotechnologies; Loxo/Lilly; Miltenyi Biotec
Travel, Accommodations, Expenses - Miltenyi Biotec
 
Wojciech Jurczak
Consulting or Advisory Role - AstraZeneca; BeiGene; Roche
Research Funding - Acerta Pharma; BeiGene; Epizyme; Janssen-Cilag; MEI Pharma; Morphosys; Roche; Sandoz-Novartis; Takeda; TG Therapeutics; TG Therapeutics
 
Pier Luigi Zinzani
Consulting or Advisory Role - ADC Therapeutics; BeiGene; Bristol-Myers Squibb; Celltrion; EUSA Pharma; Gilead Sciences; Incyte; Janssen-Cilag; Kyowa Hakko Kirin; MSD; Novartis; Roche; Sandoz; Secura BIO; SERVIER; Takeda; TG Therapeutics
Speakers' Bureau - EUSA Pharma; MSD; Novartis
 
Toby A. Eyre
Honoraria - Abbvie; AstraZeneca; Beigene; Incyte; Janssen; Kite, a Gilead Company; Loxo@Lilly; Roche
Consulting or Advisory Role - Abbvie; AstraZeneca; Autolus; BeiGene; Incyte; Janssen; Kite, a Gilead Company; Loxo@Lilly; Roche; Secura Bio
Speakers' Bureau - Abbvie; AstraZeneca; BeiGene; Incyte; Kite, a Gilead Company; Loxo@Lilly; Roche
Research Funding - AstraZeneca; BeiGene
Other Relationship - Loxo@Lilly
 
Chan Cheah
No Relationships to Disclose
 
Chaitra Shankar Ujjani
Honoraria - Abbvie; BeiGene; Genentech; incyte; Janssen; Lilly; Pharmacyclics
Consulting or Advisory Role - AstraZeneca; Atara Biotherapeutics; Epizyme
Research Funding - Abbvie (Inst); Adaptive Biotechnologies; AstraZeneca/MedImmune; Kite, a Gilead company; Lilly; Pharmacyclics (Inst)
 
Koji Izutsu
Honoraria - Abbvie; Abbvie; Allergan; AstraZeneca; Bayer; Bristol Myers Squibb; Bristol-Myers Squibb; Celgene; Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; Eisai; Fujifilm; HUYA Bioscience International; Janssen; Janssen; Kyowa Kirin; MSD; MSD; Mundipharma; Novartis; Ono Pharmaceutical; SymBio Pharmaceuticals; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; AstraZeneca; Bayer; Celgene; Kyowa Kirin; Ono Pharmaceutical
Research Funding - Chugai Pharma; Eisai
 
Shuo Ma
Honoraria - Abbvie; AstraZeneca; BeiGene; Bristol-Myers Squibb; Clinical Care Options; Curio Science; DAVA Oncology; Genentech; Janssen; Lilly O.; Medscape; OncLive; TG Therapeutics
Consulting or Advisory Role - Abbvie; AstraZeneca; BeiGene; Bristol-Myers Squibb; Genentech; Janssen; TG Therapeutics
Speakers' Bureau - AstraZeneca; BeiGene; Janssen; Lilly O.; Pharmacyclics
Research Funding - Abbvie (Inst); AstraZeneca (Inst); BeiGene (Inst); Juno Therapeutics (Inst); Loxo@Lilly (Inst); TG Therapeutics (Inst)
 
Ian W. Flinn
Consulting or Advisory Role - Abbvie (Inst); AstraZeneca (Inst); BeiGene (Inst); Century Therapeutics (Inst); Genentech (Inst); Genmab (Inst); Gilead Sciences (Inst); Great Point Partners (Inst); Hutchison MediPharma (Inst); Iksuda Therapeutics (Inst); Innocare (Inst); Janssen (Inst); Juno Therapeutics (Inst); Kite, a Gilead company (Inst); MorphoSys (Inst); Novartis (Inst); Nurix (Inst); Pharmacyclics (Inst); Roche (Inst); Seagen (Inst); SERVIER (Inst); Shanghai Yingli Pharmaceuticals (Inst); Takeda (Inst); TG Therapeutics (Inst); Unum Therapeutics (Inst); Verastem (Inst); Vincerx Pharma (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Agios (Inst); ArQule (Inst); AstraZeneca (Inst); BeiGene (Inst); Bio-Path Holdings, Inc (Inst); Bristol-Myers Squibb (Inst); CALGB (Inst); CALIBR (Inst); Celgene (Inst); City of Hope (Inst); Constellation Pharmaceuticals (Inst); CTI (Inst); Curis (Inst); Fate Therapeutics (Inst); FORMA Therapeutics (Inst); Forty Seven (Inst); Genentech (Inst); Gilead Sciences (Inst); IGM Biosciences (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Innocare (Inst); Janssen (Inst); Kite, a Gilead company (Inst); Loxo (Inst); Merck (Inst); Millennium (Inst); MorphoSys (Inst); Myeloid Therapeutics (Inst); Novartis (Inst); Nurix (Inst); Pfizer (Inst); Pharmacyclics (Inst); Portola Pharmaceuticals (Inst); Rhizen Pharmaceuticals (Inst); Roche (Inst); Seagen (Inst); TCR2 Therapeutics (Inst); Tessa Therapeutics (Inst); TG Therapeutics (Inst); Triact Therapeutics (Inst); Trillium Therapeutics (Inst); Unum Therapeutics (Inst); Verastem (Inst)
 
Alvaro Jose Alencar
Consulting or Advisory Role - Amgen; BeiGene; Epizyme; Incyte; Janssen; Karyopharm Therapeutics; Kite, a Gilead company; Seagen; TG Therapeutics
Research Funding - Loxo
 
David John Lewis
Consulting or Advisory Role - BeiGene; Janssen Oncology; Kite/Gilead
Travel, Accommodations, Expenses - Kite, a Gilead company
 
Krish Patel
Consulting or Advisory Role - Abbvie; ADC Therapeutics; AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene/Juno; Epizyme; Genentech; Kite, a Gilead company; Loxo/Lilly; Morphosys; Pharmacyclics; Seagen; TG Therapeutics
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb/Celgene; Kite, a Gilead company; TG Therapeutics
Research Funding - Aptevo Therapeutics (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Curis (Inst); Epizyme (Inst); Fate Therapeutics (Inst); Kite/Gilead (Inst); Loxo/Lilly (Inst); MEI Pharma (Inst); Nurix (Inst); Pharmacyclics (Inst); Roche/Genentech (Inst); Takeda (Inst); Trillium Therapeutics (Inst); Xencor (Inst)
 
Kami J. Maddocks
Honoraria - ADC Therapeutics; AstraZeneca/Merck; BeiGene; BMS; Celgene; Epizyme; Genentech; Genmab; Incyte; Karyopharm Therapeutics; Kite, a Gilead company; Lilly; MorphoSys; Pharmacyclics; Seagen
Research Funding - Bristol-Myers Squibb; Merck; Pharmacyclics
 
Yucai Wang
Employment - Merck (I)
Stock and Other Ownership Interests - Merck (I)
Honoraria - Kite, a Gilead company (Inst)
Consulting or Advisory Role - BeiGene (Inst); Incyte (Inst); Innocare (Inst); Janssen (Inst); Kite, a Gilead company (Inst); Lilly (Inst); Loxo (Inst); TG Therapeutics (Inst)
Research Funding - Genentech (Inst); Genmab (Inst); Incyte (Inst); InnoCare (Inst); Loxo (Inst); MorphoSys (Inst); Novartis (Inst)
 
Talha Munir
Consulting or Advisory Role - Abbvie; Alexion Pharmaceuticals; AstraZeneca; BeiGene; Janssen-Cilag; Roche; SOBI
Speakers' Bureau - Abbvie; Alexion Pharmaceuticals; AstraZeneca; Gilead Sciences; Janssen-Cilag; SOBI
Travel, Accommodations, Expenses - Abbvie; Alexion Pharmaceuticals; AstraZeneca; Janssen-Cilag
 
Andrew David Zelenetz
Honoraria - Curio Science; NCCN; OncLive/MJH Life Sciences; Oncology Information Group; PER; Plexus
Consulting or Advisory Role - AstraZeneca; BeiGene; Celgene; Coherus Biosciences; Curis; Dava Oncology; Debiopharm Group; Genentech/Roche; Gilead Sciences; Juno/Celgene/Bristol-Myers Squibb; Karyopharm Therapeutics; Kite, a Gilead company; MEI Pharma; MorphoSys; Ono Pharmaceutical; Quant Health; Sandoz; Verastem
Research Funding - BeiGene; Genentech/Roche; Gilead Sciences; MEI Pharma
 
Minna Balbas
Employment - Loxo@Lilly
Stock and Other Ownership Interests - Lilly O.
 
Donald E Tsai
Employment - Loxo@Lilly
Stock and Other Ownership Interests - Lilly O.
 
Chunxiao Wang
Employment - Lilly O.
Stock and Other Ownership Interests - Lilly O.
 
Michael Wang
Honoraria - Abbvie; Acerta Pharma; AstraZeneca; Bantam Pharmaceutical; BeiGene; Bioinvent; Breast-Gynecological International Cancer Society; Bristol Myers Squibb Foundation; CAHON; Dava Oncology; Eastern Virginia Medical School; Genmab; IDEOlogy Health; Janssen Research & Development; Kite, a Gilead company; Leukemia and Lymphoma Society; MD Education; Medscape; Meeting Minds Experts; Merck; Moffit Cancer Center; Nurix; OncLive/MJH Life Sciences; Oncology Specialty Group; Pharmacyclics/Janssen; Physicans' Education Resource; Practice Point Communications; Studio ER Congressi
Consulting or Advisory Role - Abbvie; Acerta Pharma; ADC Therapeutics; Amphista Therapeutics; AstraZeneca; Be Biopharma; BeiGene; Bioinvent; Deciphera; DTRM; Genentech; Innocare; Janssen Research & Development; Kite, a Gilead company; Leukemia and Lymphoma Society; Lilly; Merck; Milken Institute; Miltenyi Biomedicine; Oncternal Therapeutics; Parexel; Pepromene; Pepromene; Pharmacyclics/Janssen; VelosBio
Research Funding - Acerta Pharma; AstraZeneca; BeiGene; Bioinvent; Celgene; Genentech; Genmab; Innocare; Janssen Research & Development; Juno Therapeutics; Kite, a Gilead company; Lilly; Loxo; Molecular Templates; Oncternal Therapeutics; Pharmacyclics; VelosBio; Vincerx Pharma
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Dava Oncology; Kite, a Gilead company; Physicans' Education Resource